A Study of Ribavirin in the Treatment of Patients With AIDS and AIDS-Related Problems
Completed · Phase 1
Conditions studied: HIV Infections
In brief
To determine the maximum long-term dosage of ribavirin (RBV) that is safe and free of serious side effects in patients with AIDS or AIDS related illnesses. Also, to determine what effect different dosage levels have on biologic markers of efficacy, such as the amount of the AIDS virus (HIV) or number of T cells in the patient's blood. RBV is a new drug capable of inhibiting the growth of the AIDS virus in the laboratory with little effect on normal human cells. In earlier tests of RBV in AIDS patients, the drug was well tolerated and safe, and this favorable result suggested that RBV should be more extensively studied in patients with AIDS and advanced AIDS related complex (ARC).
Key facts
- Study ID
- NCT00001015
- Run by
- National Institute of Allergy and Infectious Diseases (NIAID)
- People needed
- 96
- Expected to finish
- 1990-06-01
- Last updated by the study team
- 2021-11-01
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Concurrent Medication:
- Allowed:
- Short-course therapy (7 days) with oral acyclovir.
- Short-course therapy (7 days) with ketoconazole.
- Topical medications.
- Aerosolized pentamidine for prophylactic purposes.
- Concurrent Treatment:
- Allowed:
- Blood transfusions for hemoglobin toxicity.
- Patients must have two positive HIV p24 antigen tests with titers = or > 70 picograms at least 72 hours apart and within 1 month prior to entry, the last of which must be within 2 weeks of starting therapy.
- Prior Medication:
- Allowed:
- Zidovudine (AZT), without cessation of therapy required due to intolerance.
- AZT therapy must be discontinued at least 30 days prior to study entry.
You may not qualify if…
- Co-existing Condition:
- Patients with the following are excluded:
- Active opportunistic infection, symptomatic visceral Kaposi's sarcoma (KS) or progression of KS within the month prior to entry into the study, neoplasms other than KS, basal cell carcinoma of the skin, or in situ carcinoma of the cervix. Significant diarrhea, defined as = or > 3 liquid stools per day within the past week.
- Concurrent Medication:
- Excluded:
- Ongoing systemic therapy and/or prophylaxis for an AIDS-defining opportunistic infection.
- Antineoplastic therapy.
- Other experimental medications.
- Systemic chemoprophylaxis for Pneumocystis carinii pneumonia.
- Chronic (> 7 days) oral acyclovir therapy.
- Concurrent Treatment:
- Excluded:
- Blood transfusions unless they are for = or > grade 3 hemoglobin toxicity.
- Patients with the following are excluded:
- Active opportunistic infection, symptomatic visceral Kaposi's sarcoma (KS) or progression of KS within the month prior to entry into the study, neoplasms other than KS, basal cell carcinoma of the skin, or in situ carcinoma of the cervix. Significant diarrhea, defined as = or > 3 liquid stools per day within the past week.
- Prior Medication:
- Excluded within 30 days of study entry:
- Antiretroviral agents including zidovudine (AZT).
- Biologic modifiers.
- Systemic corticosteroids.
- Prior Treatment:
- Excluded within 2 months of study entry:
- Blood transfusion except for those who have taken zidovudine (AZT) who may not have received a transfusion within the previous month.
- Active drug or alcohol abuse.
Where it is running
- Univ of California / San Diego Treatment Ctr — San Diego, California, United States
- San Francisco AIDS Clinic / San Francisco Gen Hosp — San Francisco, California, United States
- Harvard (Massachusetts Gen Hosp) — Boston, Massachusetts, United States
- Bellevue Hosp / New York Univ Med Ctr — New York, New York, United States
- Univ of North Carolina — Chapel Hill, North Carolina, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.